心衰诊断时利钠肽水平与英格兰2004-2018年住院及死亡风险
基于英格兰临床实践研究数据链的40 007例新诊断心衰患者队列(48%男性,平均年龄78.5岁),分析诊断时利钠肽水平与一年住院及1年、5年、10年死亡率的关系。高利钠肽(NT-proBNP>2000 pg/mL)者心衰相关住院调整比值比是中等水平(400-2000 pg/mL)的2.26倍(95%CI 1.98-2.59),全因死亡率在1、5、10年分别为27%、62%、82%,高于中等组的19%、50%、77%,竞争风险模型中心衰相关死亡风险每个时间点高50%。
要点
- 高基线利钠肽(NT-proBNP>2000 pg/mL)与新诊断心衰患者心衰相关住院风险增加独立相关。
- 高利钠肽组1年、5年、10年全因死亡率分别为27%、62%、82%,高于中等组的19%、50%、77%。
- 从利钠肽检测到心衰诊断的中位时间为101天(IQR 19-581)。
核心结论
- 高基线利钠肽水平与新诊断心衰患者心衰相关住院增加和生存率差相关。
主要发现
- 22 085例(55%)参与者在诊断后一年内住院。
- 高利钠肽(NT-proBNP>2000 pg/mL)者心衰相关住院调整比值比为2.26(95%CI 1.98-2.59),高于中等利钠肽(NT-proBNP 400-2000 pg/mL)者。
- 高利钠肽组1年、5年、10年全因死亡率分别为27%、62%、82%,中等利钠肽组分别为19%、50%、77%。
- 竞争风险模型显示,高利钠肽组心衰相关死亡风险在每个时间点均高50%。
- 从利钠肽检测到心衰诊断的中位时间为101天(IQR 19-581)。
临床怎么用
- 在初级保健中对疑似心衰患者检测利钠肽有助于识别高危患者并优先转诊评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Heart failure (HF) is a malignant condition requiring urgent treatment. Guidelines recommend natriuretic peptide (NP) testing in primary care to prioritise referral for specialist diagnostic assessment. We aimed to assess association of baseline NP with hospitalisation and mortality in people with newly diagnosed HF. METHODS: Population-based cohort study of 40 007 patients in the Clinical Practice Research Datalink in England with a new HF diagnosis (48% men, mean age 78.5 years). We used linked primary and secondary care data between 1 January 2004 and 31 December 2018 to report one-year hospitalisation and 1-year, 5-year and 10-year mortality by NP level. RESULTS: 22 085 (55%) participants were hospitalised in the year following diagnosis. Adjusted odds of HF-related hospitalisation in those with a high NP (NT-proBNP >2000 pg/mL) were twofold greater (OR 2.26 95% CI 1.98 to 2.59) than a moderate NP (NT-proBNP 400-2000 pg/mL). All-cause mortality rates in the high NP group were 27%, 62% and 82% at 1, 5 and 10 years, compared with 19%, 50% and 77%, respectively, in the moderate NP group and, in a competing risks model, risk of HF-related death was 50% higher at each timepoint. Median time between NP test and HF diagnosis was 101 days (IQR 19-581). CONCLUSIONS: High baseline NP is associated with increased HF-related hospitalisation and poor survival. While healthcare systems remain under pressure from the impact of COVID-19, research to test novel strategies to prevent hospitalisation and improve outcomes-such as a mandatory two-week HF diagnosis pathway-is urgently needed.
引用
- Taylor CJ, Lay-Flurrie SL, Ordóñez-Mena JM, et al. Natriuretic peptide level at heart failure diagnosis and risk of hospitalisation and death in England 2004-2018. Heart. 2021. PMID: 34183432. doi:10.1136/heartjnl-2021-319196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。